-
Mashup Score: 3Moderna’s decision to shelve vaccine plant in Kenya should encourage global south’s self-reliance, says global health adviser - 2 hour(s) ago
A decision by the drug manufacturer Moderna to drop plans to set up its first mRNA vaccine manufacturing plant outside the United States in Nairobi, Kenya, should be seen as a wake-up call to developing countries to increase their investment in vaccine and drug development, an expert has said. Madhukar Pai, a Canada research chair in epidemiology and global health at McGill University’s School of Population and Global Health, said that it was “a huge mistake” for African nations to rely on the drug industry. Pai told The BMJ that Moderna’s “U turn on manufacturing in Africa was not a surprise to anyone” given the company’s reluctance to share …
Source: www.bmj.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Financial Toxicity talk in Japanese がん治療における経について日本語での発表 - 2 hour(s) ago
Excuse my Japanese language skills,
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Patient Blood Type Is Associated With Response to Immune Checkpoint Blockade in Metastatic Cancer - 3 hour(s) ago
This article reports a series of patients with metastatic solid tumors treated with immune checkpoint blockade, focusing on associations between immune-related
Source: academic.oup.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events - 3 hour(s) ago
Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks of toxicity, specifically immune-related adverse events (irAEs). There is a need for clear, effective guidelines for the management of irAEs during ICI treatment, motivating the Society for Immunotherapy of Cancer (SITC) to convene an expert panel to develop a clinical practice guideline. The panel discussed the recognition and management of single and combination ICI irAEs and ultimately developed evidence- and consensus-based recommendations to assist medical professionals in clinical decision-making and to improve outcomes for patients.
Source: jitc.bmj.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
Background The gut microbiome impacts the efficacy of immune checkpoint inhibitor (ICI) therapy and the development of ICI-mediated diarrhea and/or colitis (IMDC). Antibiotic therapy,especially that with anaerobic activity, has profound effects on the gut microbiome. Therefore, we sought to assess the effect of antibiotics on the development of IMDC. Methods Patients who received ICI therapy from January 2016 to January 2018 were examined retrospectively. A Cox regression model was used to assess factors associated with overall survival. Results A total of 826 patients were included. Of these patients, 51.6% received inhibitors of programmed cell death protein-1 or its ligand, 32.0% received inhibitors of cytotoxic T-lymphocyte-associated antigen-4, and 16.5% received a combination of the two. IMDC occurred in 52.5% of the patients after a median of 8 weeks. Overall, 569 patients (68.9%) received antibiotic therapy. Antibiotic use at any time was associated with reduced IMDC occurrence
Source: jitc.biomedcentral.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Immune Checkpoint Inhibitor Toxicity - 3 hour(s) ago
This JAMA Insights reviews the clinical presentation and management of the most common and severe immune checkpoint inhibitor toxicities.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
Purpose To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events in patients treated with immune checkpoint inhibitor (ICPi) therapy. Methods A multidisciplinary, multi-organizational panel of experts in medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, endocrinology, urology, neurology, hematology, emergency medicine, nursing, trialist, and advocacy was convened to develop the clinical practice guideline. Guideline development involved a systematic review of the literature and an informal consensus process. The systematic review focused on guidelines, systematic reviews and meta-analyses, randomized controlled trials, and case series published from 2000 through 2017. Results The systematic review identified 204 eligible publications. Much of the evidence consisted of systematic reviews of observational data, consensus guidelines, case series, and case reports. Due to the paucity of high-quali
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
The wide range of immune-related adverse effects associated with immune checkpoint blockade can complicate this effective therapy and limit its use in patients with cancer. This review surveys the …
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse events …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Membership | IASLC - 3 hour(s) ago
The only international society dedicated solely to lung cancer research, education, and patient care, we are the IASLC.
Source: www.iaslc.orgCategories: General Medicine News, Hem/OncsTweet
Moderna’s decision to shelve vaccine plant in Kenya should encourage global south’s self-reliance & South-South efforts, says @paimadhu https://t.co/6wvFhpxXQO via @GNakweya https://t.co/88w7JI4N1b